A Phase III, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of BP16 Versus EU-Prolia® in Women with Post- Menopausal Osteoporosis
This research study is looking at a new treatment called BP16 for women who have osteoporosis after menopause. Osteoporosis makes bones weak and more likely to break. The study wants to see how BP16 compares to a medicine already in use, called Prolia®. Researchers will carefully check if BP16 works well to strengthen bones in the spine, how safe it is, and if the body handles it differently than Prolia®. They'll also look at levels of substances in the blood related to bone health and check for any bone breaks. The study involves taking medication and having regular check-ups over approximately 78 weeks, or about a year and a half.
At a glance
What is this study about?
This study is about finding the best ways to help women who have osteoporosis after menopause. When women go through menopause, their bodies stop producing certain hormones, which can sometimes lead to bones becoming weaker and more brittle. This condition is called post-menopausal osteoporosis, and it increases the risk of bones breaking easily.
The researchers want to compare a new medicine, called BP16, with a medicine that's already approved and used for osteoporosis, called Prolia®. They want to see if BP16 works just as well, or even better, at strengthening bones in the spine. They will also look at whether BP16 causes similar side effects to Prolia®, and how the body processes each medicine. This type of study, called a Phase III trial, is a crucial step to see if a new medicine can be made widely available.
Over the course of the study, participants will receive either BP16 or Prolia®, along with calcium and vitamin D supplements, which are important for bone health. The main goal is to measure how much bone density in the lower back improves after about a year. They'll also monitor other important things like bone strength markers in blood tests, how often fractures occur, and keep a very close eye on the general health and any potential side effects experienced by participants.
Key takeaways
- This study compares a new osteoporosis medicine (BP16) with an existing one (Prolia®).
- It's for women with weak bones (osteoporosis) after menopause.
- The main goal is to see if BP16 strengthens bones in the spine as well as Prolia®.
- Researchers will also check for safety, side effects, and monitor bone health over about 1.5 years.
- Participants will receive study medication, calcium, and vitamin D.
- Regular clinic visits, blood tests, and bone scans are part of taking part.
Who may be eligible?
This study is looking for women who have gone through menopause and have been diagnosed with osteoporosis. You'll need to be at least 18 years old to take part. There isn't an upper age limit mentioned, so older women are also welcome to consider joining.
To ensure your safety and that the study results are clear, there will be certain criteria that would prevent someone from joining. For example, if you have other serious health conditions that might interfere with the study medication or its assessments, you might not be eligible. This is standard for all clinical trials.
Your doctor will be able to discuss all the specific details of the eligibility criteria with you to determine if this study is a good fit for your individual health situation.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you a woman?
- Have you gone through menopause?
- Have you been diagnosed with osteoporosis?
- Are you 18 years old or older?
What does participation involve?
If you decide to take part in this study, you will be given either the new medicine (BP16) or the existing medicine (Prolia®), along with calcium and vitamin D tablets. You won't know which bone medicine you are receiving, nor will the study doctors, as it's a 'double-blind' study to keep things fair.
You'll have regular visits to the clinic for check-ups over about 78 weeks, which is roughly a year and a half. These visits will involve blood tests to check bone markers and how the medicine is affecting your body, physical examinations, and scans to measure your bone density, especially in your lower back, hips, and thigh bone. The doctors will also carefully monitor any side effects you might experience. Your health will be closely watched throughout this period.
Potential risks and benefits
Locations (6)
- —UnverifiedLatvia
- —UnverifiedEstonia
- —UnverifiedSlovakia
- —UnverifiedHungary
- —UnverifiedPoland
- —UnverifiedBulgaria
Common questions
What is osteoporosis?
Osteoporosis is a condition where bones become weak and brittle, making them more likely to break, often after menopause in women.
What kind of medicines are being tested?
The study is comparing a new medicine called BP16 with an existing one called Prolia®, both used to treat osteoporosis. Participants will also take calcium and vitamin D.
How long will the study last?
The study will last for approximately 78 weeks, which is about a year and a half, with regular clinic visits during this time.
Will I know which medicine I'm getting?
No, neither you nor your study doctor will know whether you are receiving the new medicine (BP16) or the existing one (Prolia®).
What does 'bone mineral density' mean?
Bone mineral density is a measurement of how strong and dense your bones are, which helps doctors assess your risk of fractures.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.